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doi:10.1016/j.ejvs.2011.03.007Abstract Objective: The study aimed to review the results of endovascular aneurysm repair
(EVAR) using a novel sac-anchoring endoprosthesis in patients with favourable and adverse
anatomy.
Design: This is a prospective, multicentre, clinical trial.
Materials: The Nellix endoprosthesis consists of dual, balloon-expandable endoframes, sur-
rounded by polymer-filled endobags, which obliterate the aneurysm sac and maintain endo-
graft position.
Methods: The study reviewed worldwide clinical experience and Core Lab evaluation of
computed tomography (CT) scans.
Results: From 2008 to 2010, 34 patients (age 71  8 years, abdominal aortic aneurysm (AAA)
diameter 5.8  0.8 cm) were treated at four clinical sites. Seventeen patients (50%) met
the inclusion criteria for Food and Drug Administration (FDA)-approved endografts (favourable
anatomy); 17 (50%) had one or more adverse anatomic feature: neck length <10 mm (24%),
neck angle >60 (9%) and iliac diameter >23 mm (38%). Device deployment was successful
in all patients; iliac aneurysm treatment preserved hypogastric patency. Perioperative
mortality was 1/34 (2.9%); one patient died at 10 months of congestive heart failure (CHF);
one patient had a secondary procedure at 15 months. During 15  6 months follow-up, there
were no differences in outcome between favourable and adverse anatomy patients. Follow-up
CT extending up to 2 years revealed no change in aneurysm size or endograft position and no
new endoleaks.uropean Society for Vascular Surgery, 19 September 2010, Amsterdam, The Netherlands.
du (C.K. Zarins).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
EVAR Using the Nellix Sac-anchoring Endoprosthesis 39Conclusions: Favourable and adverse anatomy patients can be successfully treated using the
Nellix sac-anchoring endoprosthesis. Early results are promising but longer-term studies are
needed.
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prosthesis in (a) standard and (b) complex aneurysm
treatment.Endovascular aneurysm repair (EVAR) has markedly reduced
procedure-related mortality and morbidity compared with
open repair.1e3 However, significant concerns persist
regarding the long-term durability and effectiveness of
endovascular repair due to endoleaks, aneurysm enlarge-
ment, endograft migration, the need for secondary proce-
dures and ongoing computed tomography (CT)
surveillance.1e7 Many of these concerns are related to the
design of currently available endografts, which are
dependent on proximal and distal fixation to exclude blood
flow to the aneurysm sac. The aneurysm sac itself remains
untreated, thus leaving a large space where blood flow may
continue, with potential endoleaks from proximal or distal
fixation zones, from the device itself or from side-branch
vessels. In addition, the untreated aneurysm sac space
provides an opportunity for the endograft to move sideways
within the aneurysm sac, resulting in angulation and
displacement of the proximal or distal fixation zones
leading to new onset of endoleaks and stent-graft migra-
tion. Indeed, sideways movement of the endograft within
the aneurysm sac is a predictor of endograft migration and
late adverse events.8,9
Moreover, not all patients with abdominal aortic aneu-
rysms are candidates for endoluminal repair due to the
need for a suitable aortic neck and non-aneurysmal iliac
arteries for endograft fixation and seal. The specific
anatomic requirements of the aortic neck and iliac arteries
for proper patient selection are contained in the instruc-
tions for use (IFU) of each aortic endograft.10e14 These
requirements exclude up to 50% of patients with aortic
aneurysms15,16 from endovascular repair, leaving surgical
repair as the only treatment option. Patients with adverse
anatomic features, such as large aortic aneurysms and
short, angulated aortic necks have inferior short- and long-
term outcomes of EVAR.17e20
The Nellix endoprosthesis is a new endoluminal device,
which is designed to treat aorto-iliac aneurysms by oblit-
erating the aneurysm sac, thus eliminating the endoleak
space, while maintaining normal flow to the lower
extremities. The endograft blood-flow lumens are sup-
ported within the aneurysm sac by polymer-filled endobags,
without the need for proximal and distal fixation. Thus, this
sac-anchoring endoprosthesis can be used to treat patients
with adverse aortic neck and iliac anatomy as well as
patients with standard neck and iliac anatomy.
The initial clinical experience in 21 patients using the
Nellix endograft revealed successful aneurysm exclusion
and good short-term results.21 This experience has now
been expanded to include additional patients with shorter
aortic necks (<10 cm) and iliac aneurysms with follow-up
information in all patients at 1 year and follow-up in some
patients extending to 2 years. The purpose of this study is
to review the worldwide clinical results using this new
endograft with independent Core Laboratory morphologicanalysis to differentiate patients with favourable and those
with adverse anatomy for endoluminal repair.
Materials and Methods
Device description
The Nellix endoprosthesis consists of dual, balloon-
expandable endoframes, each surrounded by an endobag,
which is filled with an in situ curing polymer. As illustrated
in Fig. 1, each endoframe supports the blood-flow lumen
through the aneurysm sac to the iliac arteries. The poly-
mer-containing endobags surround the flow lumen and fill
the aneurysm sac, blocking retrograde flow from side
branches. They thus eliminate the space for potential blood
flow in the aneurysm (endoleak), while anchoring the
device within the aneurysm sac to provide positional
stability. Full details of the device and clinical procedure
are described in a previous publication.21 Device design
evolved during the course of the study to include longer
length devices and fillable iliac extenders to treat common
iliac aneurysms. Commercially available iliac extenders
were used in three patients, who were treated before
Nellix iliac extenders were available.
Clinical study
The initial prospective, multicentre trial to evaluate the
performance of the Nellix endoprosthesis was conducted at
four clinical sites (Latvia, New Zealand, Venezuela and
Colombia) from 2008 to 2010. Ethical approval of study
protocol was provided by the Institutional Review Board
(IRB) at each site and each patient signed an approved
informed consent written in his/her native language. All
patients were deemed to be appropriate candidates for
Table 1 Patient demographics and comorbidities.
Number % Range
Total # Patients 34
Age (years) 71 53e84
Gender
Male 31 91
Female 3 9
Comorbidities
Hypertension 23 68
CAD (MI/Stent) 19 56
CABG 6 18
Renal insufficiency
(Creatinine > 2.0 mg/dl)
1a 3
Diabetes 4 12
Smoking 17 50
MI 9 27
Abdominal surgery/Trauma 2 6
PVD 7 21
a Following enrolment of this one subject, this criterion was
changed to require serum creatinine 2 mg/dl.
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endovascular repair using the sac-anchoring endopros-
thesis.21 Inclusion criteria for the study included one or
more of the following: aneurysm size 4.5 cm or greater,
aneurysm size twice the diameter of the infrarenal neck
and documented rate of aneurysm enlargement >10% in 1
year with aortic neck length 10 mm or greater. After review
of the clinical results from the first 21 patients, the study
protocol was modified to allow inclusion of patients with
shorter aortic necks (5 mm or greater). The study now
includes a total of 34 patients with complete 1 year follow-
up in all patients. These data have been submitted for CE
mark approval.
Data analysis
Preoperative, implant and follow-up data were collected
according to prospectively defined protocol parameters.
Clinical results were maintained in a central registry.
Contrast CT scans were performed on all patients prior to
treatment and within 30 days of treatment. Follow-up CT
scans were performed at 6, 12 and 24 months.
DICOM (Digital Imaging and Communications in Medicine)
data sets of all pre- and postoperative CT scans were sent
for independent Core Laboratory image analysis. Patients
with one or more of the following anatomic measures on
the preoperative CT scan were defined as having adverse
anatomy: aortic neck length <10 mm, aortic neck angle
>60 and common iliac artery diameter >23 mm. Follow-up
CT scan measurements included aneurysm diameter and
cross-sectional area and endograft position with respect to
the superior mesenteric artery (SMA) and vertebral body
reference points. The first post-procedure CT scan (within
30 days) was used as the baseline for comparison of quan-
titative morphological changes on follow-up CT scans.
Results are presented as the mean  standard deviation.
Statistical comparison of individual measures was per-
formed using the paired t-test or Fisher’s exact test and
significance was assumed at p < 0.05.ResultsTable 2 Summary of aneurysm characteristics.a
Characteristics Mean Range
AAA diameter (cm) 5.8 4.3e7.6
AAA volume (cc) 177.8 67.5e362.7
AAA lumen diameter (mm) 42.3 30.3e60.4
Aortic neck length (mm) 22.1 5.0e50.0
Aortic neck vessel diameter (mm) 23.5 17.5e31.0
Aortic neck lumen diameter (mm) 20.3 16.0e25.0
Aortic neck angulation () 37.4 9.1e72.0
a The measurements identified in this table are provided by
the Core Lab. Measurements may differ slightly from those
made by the clinical site at the time of enrolment.Patient population
A total of 34 patients were enrolled and treated from 2008
to 2010. Patients included 31 (91%) men and three (9%)
women with a mean age of 71  8 years (range 53e84
years). Patient comorbidities are shown in Table 1.
Aneurysm morphology
Preoperative aneurysm diameter was 5.8  0.8 cm (range
4.3e7.6 cm), with aneurysm blood lumen diameter of
4.2  0.8 cm (range 3.0e6.0 cm). Infrarenal aortic neck
diameter was 24  3 mm (range 18e31 mm) with a neck
length of 21  12 mm (range 5e50 mm); neck angle was
37  15 (range 9e72). Common iliac diameter was
>23 mm in 13 patients. Six patients had bilateral iliac
enlargement.Aortic neck length was <10 mm in eight patients (24%);
mean aortic neck length in these patients was 6.6 mm.
Aortic neck angulation was >60 in three patients (9%).
Common iliac diameter was >23 mm in one or both iliac
arteries in 13 patients (38%); four patients had common
iliac aneurysms >30 mm in diameter. A total of 17 patients
(50%) had one or more adverse anatomic features, which
have made them unsuitable candidates for EVAR using
currently available Food and Drug Administration (FDA)-
approved devices. Six patients (18%) had two or more
adverse anatomic features. Aneurysm characteristics for all
34 patients are summarised in Table 2.Patient examples
Examples of patients with favourable and adverse anatomy
are shown in Figs. 2e4. Fig. 2 shows a patient with a 5.9-cm
aneurysm with favourable anatomy. The endobags were
filled with 58 ml polymer with complete aneurysm exclu-
sion. Fig. 3 shows a patient with unfavourable anatomy.
This patient had a 7-cm aneurysm with an aortic neck
length of only 5 mm. Polymer volume of 67 ml was used to
Figure 2 Treatment of an aneurysm with favourable anatomy (a) pre-op and (b) 12-month follow-up CTA 3D reconstructions, and
(c) pre-op and (d) post-op angiograms showing complete aneurysm exclusion.
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change in aneurysm size or device position with no change
in neck morphology and no endoleak. Fig. 4 illustrates the
treatment of a patient with both iliac aneurysm and
adverse neck anatomy. This patient had a 37-mm right
common iliac aneurysm extending to the hypogastric
artery. The aortic aneurysm was treated by filling the
endobags with 60 ml of polymer and the iliac aneurysm was
treated with a Nellix extender device filled with 15 ml
polymer. The polymer-filled endobag conformed to the
contours of the iliac aneurysm and preserved blood flow in
the internal iliac artery.
Procedural results
Technical success was achieved in 100% with successful
deployment and implantation of the endoprostheses in all
34 patients. The time required to insert and implant the
device and remove the delivery system ranged from 33 to
150 min (mean time 70  32 min). Fluoroscopy time was
33  17 min (range 17e71 min) and 180  81 ml contrast
agent was used (range 110e350 ml). Mean blood loss was
165  107 ml (range 35e400 ml). Mean volume of polymerused to fill the endobags was 73  33 ml (range 18e168 ml).
Data are summarised in Table 3.
Clinical outcomes
Mortality and clinical outcomes are shown in Table 4. One
patient died during the postoperative period of multisystem
organ failure. This death was not device related, as evi-
denced by post-procedure CT scan and post-mortem
examination of the aneurysm and device. Aneurysm-related
mortality was 1/34 (2.9%). In addition, one patient died at
10 months of congestive heart failure (CHF); this patient
had a normal CT scan at 6 months. Contrast fill of a portion
of the aneurysm sac (endoleak) was noted in two patients,
and these two patients are described in detail in the
previous publication.21 One patient had a proximal type I
endoleak, which was seen on the 30-day CT scan and was
fully resolved at 60 days. There was no endoleak on the 6-
month and 12-month CT scans. The other patient had
a distal type I endoleak because the device endobag was
too short to fully fill the aneurysm sac and due to the non-
availability of Nellix iliac extenders early in the clinical
experience. This endoleak persisted with no change in
Figure 3 Treatment of a 7 cm aneurysm with unfavourable anatomy (5 mm, angulated neck) treated using the sac-anchoring
endoprosthesis, (a,b) before and (d,e) after treatment. Oblique CT cross-sectional images show no significant change in device and
endoframe position between (c) 1 month and (f) 12 months follow-up.
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vascular procedure was performed at 15 months with
placement of coils and an iliac extender, resulting in
complete resolution of the endoleak. Two of the four
patients with major adverse events had favourable
anatomy and two had adverse anatomy. There have been
no other deaths, no other major adverse events and no
additional secondary procedures.
During a mean follow-up of 15  6 months (range 7e27
months), there have been no aneurysm ruptures, no
conversions to surgery, no device migration, no aneurysm
enlargement and no new endoleaks. There are no signifi-
cant differences in outcomes between patients with
favourable anatomy and those with adverse anatomy
(p Z ns, Fisher’s exact test). The one endoleak that
resolved at 60 days occurred in the adverse anatomy group
(neck angle) and the one persistent endoleak occurred inthe favourable anatomy group (endobag too short to fully
fill the aneurysm sac).Core laboratory analysis
Results of quantitative morphologic analysis of follow-up CT
scans are shown in Fig. 5. There was no change in aneurysm
diameter or circumference at 30 days, 6 months, 12 months
or 2 years compared with baseline. There was no change in
device position relative to the SMA (longitudinal movement)
or relative to the vertebral body (lateral movement)
reference point. The average distance between the SMA
and the top of the endoframe was 16  2.7 mm (nZ 33) at
30 days, 18.4  2.8 mm (n Z 30) at 6 months and 17.4 mm
(n Z 19) and 12 months. Similarly, the position of the
Figure 4 Treatment of 6.3 cm AAA with short, funnel neck and 3.7 cm right common iliac aneurysm. (a) Pre-op 3D-CT recon-
struction and (b) Post-op angiogram. (c) Post-op angiogram showing exclusion of the iliac aneurysm with preservation of internal
iliac artery flow and (d) 3D-CT reconstruction of the common iliac aneurysm after treatment with complete exclusion of the aortic
and iliac aneurysms.
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vertebral reference point (Fig. 5).Discussion
The Nellix sac-anchoring endoprosthesis is a novel method
for the endovascular repair of aortic aneurysms. Unlike
existing endografts that rely on proximal and distal fixation
mechanisms to hold the endoluminal ‘bypass’ of the
aneurysm sac in place, the Nellix device treats the aneu-
rysm by filling the aneurysm sac, thus anchoring the device
and eliminating the endoleak space. The polymer-filled
endobags surround the blood-flow channels, providing
support within the sac without the need for proximal and
distal fixation mechanisms. This allows expansion of the
limits of endovascular aneurysm repair to patients with
aortic neck and iliac anatomy, which is not suitable for
currently available aortic endografts. It also addresses two
major limitations of current aortic endografts, namely
endoleaks and device migration.
In this study, one-half of the patients were not candi-
dates for endovascular repair, based on the IFU of current
FDA-approved aortic endografts. Nonetheless, they were
successfully treated using the sac-anchoring endopros-
thesis. There was no difference in procedural success or
clinical outcome between patients with favourableTable 3 Clinical procedural data.
Mean Std.
dev.
Range
Nellix indwelling time (min) 70 32 33e150
Fluoroscopy time (min) 33 17 1771
Contrast volume (ml) 180 81 110e350
Amount of polymer infused (ml) 73 33 18e168
Estimated blood loss (ml) 165 107 35e400
Hospital stay (days) 3.8 2.2 1e9anatomy and those with adverse anatomy. The most
common adverse anatomic feature was iliac artery diam-
eter >23 mm, which was seen in 38% of patients. Common
iliac aneurysms were readily treated with either the
primary endograft device or by adding a sac-anchoring iliac
extender. This filled and excluded the iliac aneurysm while
preserving flow to the internal iliac artery. Aortic neck
length was <10 mm in 24% of patients with an average neck
length of only 6.6 mm. Neck angulation >60 was present in
9% of patients. In one case, the endograft was placed below
the severe neck angulation at the top of the aneurysm sac
and this resulted in a transient type I endoleak at the top of
the aneurysm sac, which spontaneously sealed. There was
no increase in procedure time in patients with adverse
anatomy. As the device is not a bifurcated device, it does
not require contralateral limb cannulation, thus simplifying
the deployment procedure.
Two patients in this study were noted to have endoleaks
on the first post-procedure CT scan. These patients were
treated early in this trial and were described in detail in the
initial publication.21 Both endoleaks were limited-space
endoleaks, filling only a portion of the aneurysm sac and
pressurising only a segment of the aneurysm wall. As tension
on the aneurysm wall is directly proportional to aneurysm
size, reduction of the radius of the pressurised space would
be expected to significantly reduce aneurysm wall tension
and stress. Thus, the clinical significanceof contrast fill in the
space between a sac-filling endoprosthesis and the aneurysm
wall and an endoleak, which pressurises the entire aneurysm
sac, such as occurswith traditional stent grafts,may be quite
different. Future studies and longer follow-up will help shed
light on this question.
Of the two limited-space endoleaks in this study, one
was in a patient where the device was placed just below
a severely angulated neck, leaving a small space of unfilled
aneurysm sac. This proximal endoleak resolved spontane-
ously at 60 days and remained sealed on CT scan at 6 and 12
months. The other was in a patient where the aneurysm sac
was longer than the length of the endobag and with no
Nellix iliac extenders available, the lowermost portion of
Table 4 Summary of clinical outcomes.
Event 30 days
(0e30 days)
(n Z 34)
6 months
(31e182 days)
(n Z 33)
1 year
(183e365 days)
(n Z 32)
2 years
(366e730 days)
(n Z 5)
Total
(n Z 34)
Mortality 2.9% (1)a 0.0% (0) 3.1% (1) 0% (0) 5.9% (2)
Aneurysm-related mortality 2.9% (1)a 0% (0) 0% (0) 0% (0) 2.9% (1)
Rupture 0% (0) 0% (0) 0% (0) 0% (0) 0% (0)
Conversion to surgery 0% (0) 0% (0) 0% (0) 0% (0) 0% (0)
Device migration NA 0% (0) 0% (0) 0% (0) 0% (0)
AAA sac enlargementb NA 0% (0) 0% (0) 0% (0) 0% (0)
Any endoleak 5.9% (2) 3.2% (1) 3.1% (1) 0% (0) 5.9% (2)
Secondary interventions 2.9% (1) 0% (0) 0% (0) 20% (1) 5.9% (2)
a These events occurred in the same subject; the death is considered aneurysm-related as this occurred within the 30 days following
the intervention.
b Sac enlargement is defined as change greater than 5 mm.
Figure 5 Morphological changes over time (a) No change in aneurysm size and (b) No change in lateral or longitudinal endoframe
position. Image shows measurement technique using vertebral body as reference point.
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persisted with no change in aneurysm size and was resolved
with a secondary endovascular procedure at 15 months.
This suggests that complete filling of the aneurysm sac by
the polymer-filled endobag is needed to ensure the absence
of endoleak. There have been no type II endoleaks and no
new-onset endoleaks during the follow-up period, now
extending to 2 years.
Filling of the aneurysm sac also provides positional
stability to the endograft and resistance to migration.
Quantitative morphology showed stability of the device
during follow-up with no longitudinal or lateral positional
changes. Prior studies using computational analysis have
shown that the displacement force acting on aortic
endografts in vivo is primarily directed sideways, perpen-
dicular to the direction of blood flow rather than down-
stream in the direction of blood flow.8,9 Patients with
adverse anatomy often have increased angulation of the
aortic neck and iliac arteries and it is known that curvature
of the endograft increases the magnitude of sideways
displacement force. Thus, patients with short, angulated
aortic necks and tortuous aneurysms are more prone to
endograft migration and late complication of endovascular
repair using currently available devices.17e19 The Nellix
endoprosthesis resists this sideways displacement force and
is the first endovascular device designed taking into
consideration the in vivo displacement forces acting on
implanted endografts. No changes in sideways or longitu-
dinal position of the endograft within the aneurysm sac
were seen in this study. Thus, the Nellix endograft may
provide improved resistance to time-dependent endograft
displacement and late adverse events.
Common iliac aneurysms were readily treated using the
sac-anchoring endoprosthesis with preservation of flow in
the internal iliac artery. Treatment of iliac aneurysms with
existing devices often requires coil embolisation of the
internal iliac arteries and extension to the external iliac
artery.22e24 This can result in hip and buttock claudication
as well as severe colon and pelvic ischaemia.22e24 Sac-
anchoring iliac extenders obliterate common iliac aneu-
rysms while preserving the iliac bifurcation, thus
maintaining normal blood flow to both the internal and
external iliac arteries. Furthermore, this sac-anchoring iliac
extender may be able to treat solely the common iliac
aneurysm without the need to exclude a non-aneurysmal
aorta or contralateral common iliac artery. Future modifi-
cations of the Nellix extender designs also have the
potential to treat internal iliac aneurysms with preserva-
tion of the flow lumen.
Aneurysm exclusion by filling the aneurysm space in an
effort to prevent endoleaks has been contemplated by
several research groups.25e27 Various materials have been
used to fill the aneurysm sac including foams, polymers and
glues, but none have used a fill-containment system. The
Nellix device is the first aortic endoprosthesis using a non-
porous, malleable endobag designed to contain the poly-
mer, both acutely and in the long-term, while filling the
aneurysm sac. The endobag adapts to the contours of the
aneurysm sac, obstructing side branches exiting the aneu-
rysm, thus preventing endoleaks. In addition to eliminating
endoleaks, the polymer-filled endobags support and main-
tain long-term positional stability of the endograft flowlumens. Thus, the primary concerns regarding long-term
durability of endovascular repair, namely migration and
endoleaks, are addressed by this device.
No changes in aneurysm sizewere noted in this study,with
a follow-up of 2 years in five patients. While longer-term
studies are clearly needed, these initial results suggest that
theNellix sac-anchoring endoprosthesismay allowexpansion
of patient selection criteria and provide an opportunity to
treat aneurysms, which cannot currently be treated with
existing devices. Such anatomies include no-neck or funnel-
neck aneurysms, severely angulated and tortuous anato-
mies, large-diameter aneurysms and necks and common and
internal iliac aneurysms. The elimination of type II endoleaks
during the follow-up period has the potential to reduce costs
by eradicating the need for secondary interventions. In
addition, the ability to achieve long-term device positional
stabilitymay reduce the need for annual CTscan follow-up or
may allow for the use of non-radiation, non-contrast imaging
modalities such as duplex ultrasound.
Conclusions
Patients with both favourable and adverse aneurysm
anatomy can be successfully treated using the Nellix sac-
anchoring endoprosthesis. This may expand the population
of patients who are candidates for endoluminal aneurysm
repair, may minimise or eliminate endoleaks and may
reduce the need for secondary interventions. Initial results
are encouraging but further studies with a longer follow-up
time are needed.
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